How much oncology is on the PEBC exam?

Oncology is one domain among many and is randomized throughout the multiple-choice exam, so the exact count varies by sitting. It tends to focus on the pharmacist's role: supportive care, chemotherapy-induced nausea and vomiting, oncologic emergencies, and safety, rather than on selecting chemotherapy regimens.

What oncology topics should I prioritize?

Prioritize chemotherapy-induced nausea and vomiting (CINV) prophylaxis by emetogenic risk, recognition and first steps for oncologic emergencies (febrile neutropenia, tumor lysis syndrome, spinal cord compression, hypercalcemia), common chemotherapy toxicities and their monitoring, and supportive-care counselling.

Do I need to memorize chemotherapy regimens for the PEBC?

No. The exam tests the pharmacist's role, not oncologist-level regimen selection. Focus on side-effect management, safe handling and counselling, drug interactions, and recognizing when a presentation is an emergency that needs urgent action.

PEBC Oncology Practice Questions

Oncology on the PEBC is less about prescribing chemotherapy and more about the pharmacist's real role: managing side effects, preventing and treating nausea and vomiting, recognizing oncologic emergencies, and supporting patients safely through treatment.

Work through the questions below. Each one shows why the right answer is right and why every wrong answer is wrong, so you can build the pattern recognition the exam rewards.

Written and reviewed against current Canadian guidelines and references.

free questions here

no signup to start

All 4

options explained

How to approach PEBC oncology questions

1Anchor on the pharmacist's job: supportive care, safety, and counselling, not choosing the regimen. Most marks live in side-effect management and monitoring.
2Know chemotherapy-induced nausea and vomiting (CINV) cold: match the prophylaxis to the emetogenic risk, and know where agents like olanzapine and the NK1 antagonists fit.
3Recognize oncologic emergencies fast: febrile neutropenia, tumor lysis syndrome, spinal cord compression, and hypercalcemia each have a time-sensitive first action.
4Tie classic toxicities to their drugs and their monitoring: the EGFR-inhibitor rash, anthracycline cardiotoxicity, and the agents that demand specific premedication.
5When two answers look defensible, pick the one that is safest for the patient first, then most guideline-consistent.

Practice questions

Tap an answer to see why each option is right or wrong.

Question 1Chemo-Induced Side Effects

Which skin pattern best fits EGFR inhibitor rash?

Incorrect · Answer: C

PEBC Yield: Low-Medadr-recognitiondiagnosis-classificationmonitoringscreening

This fits hand-foot syndrome more than EGFR inhibitor rash.

This fits extravasation injury more than EGFR inhibitor rash.

C) (Correct)

Correct. EGFR rash presents with erythema, edema, papulopustular eruptions, then crusting and skin dryness.

This suggests a hematologic bleeding pattern rather than EGFR inhibitor rash.

Question 2CINV

In high-emetogenic chemotherapy prophylaxis, where does olanzapine fit?

Incorrect · Answer: A

PEBC Yield: Highprophylaxis

A) (Correct)

Correct. Olanzapine is a first-line component for acute and delayed CINV prophylaxis with highly emetogenic chemotherapy.

Minimal-risk prophylaxis component is a close distractor, but minimal-risk chemotherapy generally does not need routine prophylaxis

Simple nausea first-line agent is a close distractor, but olanzapine is not a simple nausea first-line agent

NK1 substitute in NEPA is a close distractor, but NEPA contains netupitant and palonosetron, not olanzapine

Question 3Oncologic Emergencies

Which finding is LEAST appropriate as an initial vancomycin add-on trigger in febrile neutropenia?

Incorrect · Answer: A

PEBC Yield: Low-Meddrug-selectionempiric-therapypathogen-coveragemonitoring

A) (Correct)

Correct. Stable fever at 12 hours without gram-positive, line, MRSA, mucositis, or hemodynamic clues is not an initial vancomycin trigger.

A suspected venous access catheter infection is a reason to include vancomycin initially.

Known MRSA colonization is a reason to include vancomycin initially.

Hypotension or cardiovascular impairment supports adding vancomycin initially.

Question 4Oncology

In TNM staging, which T-category notation means the main tumor cannot be measured?

Question 5Chemo-Induced Side Effects

Which prevention advice best fits hand-foot syndrome during cancer therapy?

Question 6CINV

Which home route can be useful when an outpatient is vomiting and cannot take oral medication?

Incorrect · Answer: A

PEBC Yield: Highroute-selectionbreakthrough-cinv

A) (Correct)

Correct. Rectal prochlorperazine can be useful at home when vomiting prevents oral antiemetic use.

Oral aprepitant is a close distractor, but oral aprepitant may not be feasible if the patient cannot keep oral medication down

Oral dexamethasone is a close distractor, but oral dexamethasone may not be feasible during active vomiting

Oral nabilone is a close distractor, but oral nabilone may not be feasible during active vomiting

Question 7Oncologic Emergencies

Which feature is LEAST consistent with high tumor lysis syndrome risk before therapy?

Incorrect · Answer: A

PEBC Yield: Low-Medscreeningdiagnosis-classificationmonitoringprophylaxis

A) (Correct)

Correct. A localized indolent tumor is less consistent with high TLS risk than bulky, rapidly proliferating, renal-risk, or hyperuricemic settings.

Bulky disseminated malignancy is a classic high-risk feature for TLS.

Pre-existing hyperuricemia increases concern for TLS and supports preventive planning.

Pre-existing renal impairment increases concern for TLS complications and supports preventive planning.

Question 8Oncology

Which mechanism best matches vinca alkaloids?

Question 9CINV

PW is a 72 year old male with non-small cell lung cancer receiving carboplatin AUC 5 plus pemetrexed. He has COPD, osteoarthritis, and CKD stage 3a. Current medications include tiotropium 18 mcg inhaled daily, acetaminophen 500 mg po q6h prn, and amlodipine 10 mg po daily. Which antiemetic regimen is most appropriate for prevention of acute CINV in this patient?

Incorrect · Answer: A

PEBC Yield: Highdrug-selectionprophylaxis

A) (Correct)

Correct -- carboplatin at AUC 5 or higher is classified as high emetogenic risk per NCCN guidelines. High-risk regimens require a quadruple regimen: 5-HT3 antagonist plus dexamethasone plus NK1 antagonist plus olanzapine for optimal acute CINV prevention.

Metoclopramide combined with dexamethasone is an option for low emetogenic risk prophylaxis. This is insufficient coverage for a high-risk regimen.

This triple regimen would be appropriate if carboplatin AUC were less than 4 (moderate risk). At AUC 5, this regimen omits olanzapine, which is recommended as part of the high-risk quadruple regimen.

A dual regimen with 5-HT3 plus dexamethasone is appropriate for moderate emetogenic risk. Carboplatin AUC 5 exceeds the threshold for moderate risk classification.

Question 10Oncologic Emergencies

Which hypercalcemia intervention is LEAST appropriate as a default early step?

Incorrect · Answer: C

PEBC Yield: Low-Meddrug-selectionmonitoringurgency-referralcontraindication-check

Hydration is a core early treatment for hypercalcemia.

IV bisphosphonates are core therapy for hypercalcemia of malignancy.

C) (Correct)

Correct. Routine loop diuretic use is discouraged because it can worsen extracellular fluid depletion.

Calcitonin is useful as rapid bridging therapy in severe hypercalcemia.

Question 11Oncology

A 64-year-old male with metastatic renal cell carcinoma has been receiving pembrolizumab for 8 weeks. He presents with new-onset fatigue, cold intolerance, weight gain, and constipation. His TSH is 14.2 mIU/L (normal 0.5-4.5) and free T4 is 6.1 pmol/L (normal 10-25). Which of the following best explains this presentation?

Incorrect · Answer: B

PEBC Yield: Low-MedADR-recognitionmonitoring

Pembrolizumab is a monoclonal antibody that does not interact with thyroid hormone supplements through pharmacokinetic mechanisms. There is no known drug interaction causing this presentation.

B) (Correct)

Correct -- immune checkpoint inhibitors such as pembrolizumab block checkpoint proteins and boost immune activity, which can cause immune-mediated adverse effects affecting any organ. Thyroiditis leading to hypothyroidism is among the most common endocrine toxicities of this drug class.

While paraneoplastic syndromes can occur with renal cell carcinoma, they more commonly cause hypercalcemia or erythrocytosis. The temporal relationship with pembrolizumab initiation strongly suggests an immune-mediated cause.

Checkpoint inhibitors are not cytotoxic agents. They work by enhancing the immune response against cancer cells. The thyroid damage is immune-mediated through autoimmune inflammation, not direct cellular toxicity.

Question 12CINV

Which option is EXCEPTED from serious antiemetic safety monitoring examples?

Incorrect · Answer: B

PEBC Yield: Highmonitoringadr-recognition

QT prolongation is a close distractor, but QT prolongation is a serious safety endpoint

B) (Correct)

Correct. Mild taste preference is not a serious antiemetic safety endpoint.

Extrapyramidal side effects is a close distractor, but extrapyramidal side effects are serious dopamine antagonist safety concerns

Torsades risk is a close distractor, but torsades risk follows from clinically important QT prolongation

Want the full bank?

These are a sample. The full bank adds full-length cases and timed mock exams.

Frequently asked questions

How much oncology is on the PEBC exam?: Oncology is one domain among many and is randomized throughout the multiple-choice exam, so the exact count varies by sitting. It tends to focus on the pharmacist's role: supportive care, chemotherapy-induced nausea and vomiting, oncologic emergencies, and safety, rather than on selecting chemotherapy regimens.
What oncology topics should I prioritize?: Prioritize chemotherapy-induced nausea and vomiting (CINV) prophylaxis by emetogenic risk, recognition and first steps for oncologic emergencies (febrile neutropenia, tumor lysis syndrome, spinal cord compression, hypercalcemia), common chemotherapy toxicities and their monitoring, and supportive-care counselling.
Do I need to memorize chemotherapy regimens for the PEBC?: No. The exam tests the pharmacist's role, not oncologist-level regimen selection. Focus on side-effect management, safe handling and counselling, drug interactions, and recognizing when a presentation is an emergency that needs urgent action.